| | | 20,000+ Fresh Resumes Monthly | |
|
|
| |
Click here or scroll down to respond to this candidate1Updated Street Address /15/2020CURRICULUM VITAEName and Address: Prem L. SharmaStreet Address .PHONE NUMBER AVAILABLE (Mobile)EMAIL AVAILABLEEMAIL AVAILABLECitizenship: U.S.A.Education:1974 B.Sc. Medical Laboratory Technology (Hons), All-India Institute of Medical Sciences, New Delhi, India.1979 M.Sc. Microbiology, Haryana Agricultural University, Hissar, India. Thesis: Studies on the enterotoxin production by Bacillus cereus. Haryana Agricultural University, Hissar, India 1979.Major: Microbiology; Minor: Veterinary Bacteriology 1985 Ph.D. Medical Microbiology, Lady Hardinge Medical College, Delhi University, India. Thesis: Epidemiology of R-plasmids encountered in Salmonella species of human origin. Delhi University, Delhi, 1984.US Equivalency Ph.D. Microbiology (World Education Service Inc., New York)) Summary of Skills: Supervisory/IRB/Biosafety/Grant Management 08/1999- Developed SOPs for various research projects according to OSHA/CDC requirements; Supervised and trained junior scientists in BSL-2 practices; serving on Atlanta VA Medical Center Safety Research Sub-committee (SRS) since 2001; served as a Chairperson for SRS(2009-2011) (10-15 members committee); served as Biosafety Officer for 6 months; serving on Institutional IRB for the past five years; interacted with institutional and federal agencies to manage the federal grants to accomplish the goals of specific project; supervised and trained BS/MS/MD/Ph.D. level scientists in research methodology; expertise in biological assays related to virology, bacteriology, recombinant DNA technology (cloning), protein expression and cell biology (transfection), viral cell culture assays; formal skills in teaching and training; extensive clinical Microbiology Laboratory experience with QA/QC; collaborated with internal and external faculty to accomplish the goals of the projects. Title and affiliations and job-related Skills:09/2013- Medical Technologist-Microbiology-PRN, Piedmont Hospital, Atlanta, GA Processing various body fluids for microbiological analysis at Piedmont hospital: performing weekly and daily QCs on Microscan for the ID/antibiotic susceptibility of Gram positive, Gram negative and Rapid ID panels; performing new lot QCs for various panels received in the laboratory; plating various clinical specimens and reading Gram stains; processing positive blood cultures and communicating with Nurse/Dr.; reading STAT CSF Gram stain and India ink and wet preps for Trichomonas; performing PCR on GeneXpert Infinity and BioFire instrument ; completing competency requirements on-hand and on-line; performing daily and weekly maintenance of various laboratory instruments; communicating with other colleagues, nurses and Physicians as required; following biosafety and safety procedure of laboratory01/2020- Medical Technologist (Microbiology), Quest Diagnostics, Tucker, Atlanta Working on Throat and Strep B bench. Identification of Group B streptococcus (GBS) from Rectovaginal swabs and performing Strep B sensitivity to antibiotics using VITEK 2 system. Identification of various groups of Streptococcus using STREPTEX Latex grouping system 2and performing antibiotic susceptibility using VITEK 2 system. Advanced knowledge of Quality Control of Diagnostic Bacteriology Laboratory: performing QC for reagents and media received in laboratory; maintaining a series of aerobic and anaerobic QC organisms. Performing QC for new lot Matrix and slides using MALDI-ID system. 09/2004-09/2015: Assistant Professor, Department of Microbiology and Immunology, Emory University School of Medicine, and Research Microbiologist, Veterans Affairs Medical Center, Atlanta, GAProject: Analyses of incompatibility among drug-selected RT mutations: Received VA Merit grant to study impact of Drug resistance mutations in HIV replication and enzyme activity; Performed regularly- cell cultures in BSL-2 facility; routinely performed PCR/real-time PCR, site-directed mutagenesis, cloning, mammalian cell transfections with full-length proviral clones; supervised post-doctoral fellows, undergraduate students and research specialists; presented research data in scientific meetings; served as a member of biosafety, R&D and IRB committees; interacted with internal and external investigators when required to accomplish the goals of research projects.09/1999-09/2004: Assistant Professor, Department of Pediatrics, Emory University School of Medicine, Atlanta, GAProject: Studies to analyze the role of drug-selected mutations in HIV-1 replication fitness: Received RO1 grant from NIH mechanism to study impact of Drug resistance mutations in HIV replication and enzyme activity; Performed regularly cell cultures in BSL-2 facility; routinely performed PCR/real-time PCR, site-directed mutagenesis, cloning, mammalian cell transfections with full-length proviral clones; supervised post-doctoral fellows, undergraduate students and research specialists; presented research data in scientific meetings; served as a member of biosafety, R&D and IRB committees; interacted with internal and external investigators when required to accomplish the goals of research projects.Formal Teaching:1997-1998 Lecturer (part time), Northeastern University, Boston. Courses: Introduction to Immunodiagnostics and Introduction to Recombinant DNA Technology.Summer 2013- Instructor (part time) Georgia Perimeter College, Dunwoody, GA. Course: Microbiology Laboratory and Lecture (pre -Nursing, pre-PA, pre-Dental Hygiene, pre- Anesthesia assistant students).Professional Certifications:Since May 2007 American Medical Technologist-MT (AMT) Committee Memberships:a) National and International:2001-2003 Reviewer for Elizabeth Glaser Pediatric AIDS Foundation grants. 2001- Ad hoc Reviewer for Journals: Virology, Nucleic Acids Research (since Clinical Microbiology, Clinical Virology and Antimicrobial Agents and Chemotherapy. 2001- Managing Editor for the Journal Frontiers in Bioscience 2003-2011 Editorial Board of Journal of Clinical Microbiology. 2008- Study Board Member for Career Development Award, Clinical/ Biomedical Research and Development Services, Department of Veterans Affairs, Washington, DC. 2009- ad hoc reviewer for NIH challenge grants ZRG1 IMM-E (58). 2009- ad hoc reviewer for VA Infectious Diseases VA MERIT Review. 2010- Associate Editor- Journal of Clinical Virology b) Institutional:2000- Member for the CFAR at Emory University.32001- Member of the Research Safety Subcommittee of VA Medical Center, Atlanta. 2008-2012 Ad-hoc member of Research and Development Services, Veterans Affairs Medical Center, Decatur, GA2008-2009 Member of University Senate Diversity Subcommittee 2009-2010 Member of University Senate Diversity Subcommittee and Chair, Diversity Website Content Development subcommittee.2009- Member of Emory University IRB Committee2010-2012 Chairperson, Safety Research Sub-Committee, Atlanta VA Med. Center 2010-2012 Member R & D Committee, Atlanta VA Medical Center. 2011-2012 Acting Research Biosafety Officer and Chemical Hygiene Plan Officer Awards/Honors:1980-1982 Junior Research Fellowship, Indian Council of Medical Research, New Delhi, India 1982-1984 Senior Research Fellowship, Indian Council of Medical Research, New Delhi, India 1993 Howard Temin Prize for best Basic Science Contribution to the J. AIDS during 1993 (Ref.#15)Society Memberships:Since 2001 American Society of MicrobiologistsSince 2001 American Association for the Advancement of Science Grant Support:a) Previous Support:1. Title: Characterization of HIV integration in relation to viral attenuation Principal Investigator: Prem L. Sharma, Ph.D.Agency and Type: VA MERIT REVIEW (08-20-2007 to 07-31-2011) 2. Title: Role of multidrug resistance mutation in HIV fitness Principal Investigator: Prem L. Sharma, Ph.D.Agency and Type: NIH NIAID RO1 AI 47726-01A1 (07-01-00 to 06-30-2003; no-cost extension 06-30-2004). 3. Title: Detecting early emerging drug-resistant HIV populations Principal Investigator: Prem L. Sharma, Ph.D.Agency and Type: NIH NIAID 1 R41 AI058888-01 (STTR) (3-13-2004 to 2-28-2005) Supervisory Teaching (partial list):Feb. 2008-Dec. 2011 HimaBindu Chunduri, Ph.D., Post-doctoral Fellow 2008-Summer Viktoria Nurpeisov, MD (Feb-May), Schedule Student 2002-2004 Viktoria Nurpeisov, Summer student (2nd year MD student). 1993-1999 7 undergraduate and graduate studentsLectureship, Seminar Invitations, and Visiting Professorships (partial list): 2012 Georgia State University, Dept. of Biology, Center for Therapeutics and Diagnostics, Georgia The impact of the Reversion of HIV-1 RT Mutations on Viral Replication, October 18, 2012. 2012 Veterans Affairs Medical Center, Atlanta Can we use HIV-1 drug resistance to our advantage, March 3, 2012.2011 Philadelphia College of Osteopathic Medicine, Georgia Campus "Can we use HIV-1 Drug Resistance to our Advantage", February 7, 2011.2005 Texas A & M University at Corpus Christi. Impact of Incompatible RT Mutations on HIV-1 Replication Fitness. May 2, 2005.2005 Miniority Health Institute and Health Disparities-Project Export, Bluefield State College, West Virginia Incompatibility among HIV-1 Reverse Transcriptase mutation: Clinical Implications April 27, 2005.42005 Applied Biosystem-Applera, San Francisco, CA Quantification and Molecular analyses of human pathogenic bacteria and viruses-Biodefense prospective; January 31, 2005 2004 Washington State University, Pullman: Role of Biosafety Officer in University; October 18, 2004. 2001 Emory University, ID seminar series: "Role of HIV-1 RT mutations in viral fitness"; January 18, 2001.1999 University of Des Moines, Iowa1999 VA Hospital, Emory University, Atlanta, June 30, 1999 1998 Health Science Center at Dallas, September 8, 1998 1998 NIH Clinical Center, April 9, 19981993 FDA Biological Research Center: Post-exposure prophylaxis and prevention of retroviral infection: analysis at DNA level.Bibliography:1. Sharma PL, Sharma KB, Prakash K. 1984. Molecular studies on drug resistant plasmid of Salmonella typhi: A preliminary report. Indian J Med Microbiol 2:57-61.2. Sharma PL, Sharma KB, Prakash K. 1984. Incidence of conjugative plasmids amongst multidrug resistant Salmonella typhimurium strains isolated from different parts of India (1979-1982). Indian J Med Res 79:473-478. 3. Sharma PL, Sharma KB, Prakash K. 1984. Colicin production and coexistence of Col-plasmid with R-plasmid in Salmonellae. Indian J Med Res 79:473-478.4. Sharma PL, Sharma KB, Prakash K. 1984. Autotransferable sulfamethoxzole and trimethoprim resistance in Salmonella oranienburg strains isolated during epidemics in Delhi and Bombay. Indian J Med Res 80:396-401. 5. Sharma PL, Sharma KB. 1984. Deletion and partial loss in pVA517A: A32 Md plasmid of Escherichia coli. Indian J Med Microbiol 2:153-155.6. Panhotra BR, Desai B, Sharma PL. 1985. Nalidixic acid resistance in Shigella dysenteriae type I. Lancet 1:763. 7. Sharma PL, Sharma KB, Prakash K. 1985. Molecular study of plasmids in relation to incompatibility groups. Indian J Med Microbiol 3:261-265.8. Sharma PL, Sharma S, Prakash K, Sharma KB. 1988 Genetic and molecular characterization of an epidemic plasmid coding for multidrug resistance in Salmonella typhimurium of human origin. Plasmid 20:10-16. 9. Mohan VP, Diwan N, Sharma PL, Agarwal DS. 1988. Resistance plasmids in Salmonella senftenberg, Indian J Med Microbiol 6:107-110.10. Sharma PL, Sharma KB. 1989. Occurrence of heterogeneous R-plasmids during two concurrent epidemics due to multidrug-resistant Salmonella oranienburg. Current Microbiol 19:3-6. 11. Ruprecht RM, Mullaney S, Bernard L, Gama Sosa MA, Fazely F, Koch J, Sharma PL, Chou TC. 1990. Review: Murine models for evaluating antiretroviral therapy. Cancer Res (Suppl) 50:5618s-5627s 12. Viglianti GA, Sharma PL, Mullins JI. 1990. Simian immunodeficiency virus displays complex patterns of RNA splicing. J Virol 64:4207-4216.13. Gama Sosa MA, DeGasperi R, Kim Y-S, Fazely F, Sharma PL, Ruprecht RM. 1991 Serine phosphorylation-independent down regulation of cell-surface CD4 nef. AIDS Res Hum Retroviruses 7:859-860. 14. Ruprecht RM, Koch JA, Sharma PL, Armany RS. 1992. Development of antiviral treatment strategies in murine models. AIDS Res Hum Retroviruses 8:997-1011.15. Fazely F, Sharma PL, Fratazzi C, Greene MF, Wyand M, Memon MA, Penninck D, Ruprecht RM. 1993. Simian immunodeficiency virus infection via amniotic fluid: A model to study fetal immunopathogenesis and prophylaxis. J AIDS 6:107-114.16. Wang SP, Sharma PL, Schoenlein PV, Ely B. 1993. A histidine protein kinase is implicated in polar organelle development in Caulobacter crescentus. Proc Natl Acad Sci USA 90:630-634. (First two authors have equal contribution to this manuscript).17. Ruprecht RM, Fratazzi C, Sharma PL, Greene MF, Penninck D, Wyand M. 1993. Animal models for perinatal transmission of pathogenic viruses. Ann NY Acad Sc 693:213-228. 18. Sharma, PL, Chatis, PA, Dogon, AL, Mayers, DL, McCutchan, FE, Page, C. & Crumpacker, CS. 1996. AZT-related mutation Lys70Arg in reverse transcriptase of HIV-1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assays. Virology 223:365-369.19. Ruprecht, RM, Hu, Y, Liska, V, Rasmussen, R & Sharma PL. 1996. Correlates of immune protection after vaccination with attenuated live murine leukemia virus. AIDS Res. Hum Retroviruses 12:375-377. 20. Ruprecht, RM, Baba, TW, Li, A, Ayehunie, S, Hu, Y, Liska, V, Rasmussen, R, & Sharma PL. 1996. Live attenuated HIV as a vaccine for AIDS: pros and cons. Seminars in Virol 7:147-155. 21. Ruprecht, RM, Baba, TW, Rasmussen, R, & Sharma PL. 1996. Murine and simian retrovirus models: the threshold hypothesis. AIDS 10:33-40.522. Zhang, LJ, Sharma, PL, Li, CJ, Dezube, BJ, Pardee, AB, & Crumpacker, CS. 1997. Topotecan inhibits HIV-1 infection in cells with altered topoisomerase I. Antimicrob Agents Chemother 41:977-981. 23. Sharma PL, Crumpacker, CS. 1997. Attenuated replication of HIV-1 with a didanosine-selected reverse transcriptase mutation J Virol 71:8646-8651.24. Zhang JL, Choe H, Dezube BJ, Farzan M, Sharma PL, Chen LB, Ono M, Gilles S, Wu Y, Sodroski JG & Crumpacker CS. 1998. The Bis-Azo dye FP-21399 inhibits HIV-1 replication by preventing viral entry. Virology 244:530-541. 25. Chou S, Lurain NS, Weinberg A, Crumpacker CS, Cai GY, Sharma PL, Drew WL and Adult ACTG CMV Laboratories. 1999. Analysis of interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on the genotypic diagnosis of antiviral drug resistance. Antimicrob Agents and Chemother 43:1500-1502. 26. Rasmussen RA, Sharma PL, Hu Y & Ruprecht RM. 1999. Vaccine protection by subinfectious doses of a live murine leukemia virus. Leukemia 13:94-5.27. Sharma PL & Crumpacker CS. 1999. Decreased processivity of RT containing a didanosine selected RT mutation: comparative evaluation of the effect of RT mutations Leu74Val and Met184Val on viral fitness and RT processivity. J Virol 73:8448-8456.28. Zhang JL, Sharma PL & Crumpacker CS. 2000. Enhancement of the basal level activity of HIV-1 long terminal repeat by HIV-1 nucleocapsid protein. Virology 268:251-263.29. Oram, RJ, Marcellino D, Strauss D, Gustafson E, Talarico CL, Root AK, Sharma PL. Thompson K, Fingeroth JD, Crumpacker CS & Herold BC. 2000. Characterization of an acyclovir-resistant herpes simplex virus type 2 strain isolated from a premature neonate. J Infect Dis 181:PHONE NUMBER AVAILABLE Nurpeisov V, Hurwitz SJ, and Sharma PL. 2003. Development of fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of viruses containing mutations at HIV-1 reverse transcriptase codons 74 and 184. J Clin Microbiol. 41:3306-3311.31. Sharma PL, Nurpeisov V, Lee K, Skaggs S, Amat C, and Schinazi RF. 2004. Replication dependent 65R K reversion in human immunodeficiency virus type 1 reverse transcriptase double mutant K65R + L74V. Virology 321:222-234. 32. Sharma PL, Nurpeisov V, Hernandez-Santiago B, Beltran T, and Schinazi RF. 2004. Nucleoside inhibitors of HIV reverse transcriptase. Current Topics in Medicinal Chemistry, 4:895-921. 33. Sharma PL, Nurpeisov V, and Schinazi RF. 2005. Retrovirus reverse transcriptases containing modified YXDD motif. Antiviral Chem Chemother 16:169-182.34. Moser MJ, RLarsen CA, Swearingen AJ, Kozlowski M, Sharma PL, Schinazi RF, and Prudent JR. 2005. Quantifying mixed populations of drug resistant human immunodeficiency virus type-1. Antimicrob Agents Chemother 49:3334-3340. 35. Sharma PL, Nettles J, Feldman A, Kimberly R, and Schinazi RF. 2009. Comparative processivity of HIV-1 reverse transcriptases containing K65R, L74V, M184V and 65R + 74V mutations. Antiviral Res. 83:317-323. 36. Chunduri HB, Nurpeisov V, Crumpacker C, Rimland D, and Sharma PL. 2011. A leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus. Virology J. 8(1):33. 37. Chunduri HB, Crumpacker C and Sharma PL. 2011. Reverse transcriptase mutation K65N confers a decreased replication capacity to HIV-1 in comparison to K65R due to a decreased RT processivity. Virology 414:34-41. 38. Sharma PL, Chunduri HB, Mindley R, and Rimland D. 2012. Up-regulation of specific anti-apoptosis marker genes in PBM cells infected with HIV-1 RT mutants. Viral Immunol 25:12-20. 39. Chunduri HB, Rimland D, Nurpeisov V, Crumpacker C, and Sharma PL. Differential reversion kinetics of HIV-1 reverse transcriptase key mutations: A mechanism for the prevalence of nucleoside analog-selected mutations in patients (In preparation).Other publications (conference Abstracts):1. Sharma PL, Prakash K, Sharma KB. Genetic characterization of drug resistant plasmids of Salmonella indiana. The Vth National Congress of Indian Association of Medical Microbiologists, Calcutta, December 1982. 2. Sharma PL, Sharma KB, Prakash K. Genetic characterization of R-plasmids in multidrug resistant Salmonella typhimurium strains isolated in India. XV International Congress of Genetics, New Delhi, 12-21, December, 1983. 3. Sharma PL, Sharma KB, Prakash K. Plasmid-mediated colicin production and its coexistence with R-plasmid in Salmonella species. XV International Congress of Genetics, New Delhi, 12-21 December, 1983. 4. Sharma PL, Sharma KB, Prakash K. Molecular epidemiology of R-plasmids of Salmonellae isolated in India. In : Programme, papers and abstracts of Third Asian Conference on Diarrhoeal Diseases, Bangkok, Thailand, 10-14 June 1985:211. Salmonella Phage typing Center, Lady Hardinge Medical College, New Delhi, 11 0 001. (Published In J Diarrhoeal Dis. Res. December 1985).65. Ruprecht RM, Hom RC, Sharma PL, Finberg RW, Mullaney S, Bernard LD. Vaccination with a live retrovirus: The role of T-cell subsets. International AIDS Conference, San Francisco, California, June, 1990. 6. Sharma PL, Armany R, Ruprecht RM. Post-exposure prophylaxis and prevention of retroviral infection: analysis at the DNA level. Cold Spring Harbor Meeting on RNA Tumor Viruses in May 1992 (Oral presentation). 7. Fratazzi C, Sharma PL, Lambert RW, Green MF, Wyand MS, Pennick D, Ruprecht RM. SIV-gag and nef-specific CTL responses in infected rhesus monkey mother/infant pairs. Cold Spring Harbor Meeting on RNA tumor viruses, 1993.8. Sharma PL, Chatis PA, Dogon AL, Crumpacker CS. Significance of mutations Lys70Arg and Lys65Glu observed following Zidovudine (AZT) and 2,3 dideoxyinosine (ddI) therapy. The Second National Conference on Human Retroviruses and Related Infections, Washington, D.C. Jan. 29-Feb. 2, 1995. 9. Zhang L, Sharma P, Crumpacker C. Topotecan inhibits HIV replication in a topotecan resistant cell line and induces mutations in HIV-1 LTR. The Second National Conference on Human Retroviruses and Related Infections, Washington, D.C. Jan. 29-Feb. 2, 1995.10. Sharma PL, Crumpacker CS. Comparision of replication kinetics of HIV-1 RT variants in PBMC culture in drug free medium. The Third National Conference on Human Retroviruses and opportunistic infections, Washington, D.C. Jan, 28-Feb. 2, 1996 (Oral presentation).11. Zhang LJ, Wu J, Dezube BJ, Sharma PL, Ono M, Gillies SD, Chen BL, and Crumpacker CS. A Bis-Azo-Dye (FP- 21399) inhibits HIV-1 replication in the post-absorption stage. The 4th National Conference on Retroviruses and opportunistic infections, Washington, D.C. Jan, 22- 26, 1997. 12. Sharma PL, Crumpacker CS. Didanosine-selected mutation Leu74Val in HIV-1 reverse transcriptase confers a loss in fitness to the virus in PHA-stimulated PBMC in the absence of drug. The 4th National Conference on Retroviruses and opportunistic infections, Washington, D.C. Jan, 22- 26, 1997. 13. Sharma PL, Crumpacker CS. Comparison of viral fitness in viruses with 3TC-selected mutation Met184Val and ddI- selected mutation Leu74Val. The 5th National Conference on Retroviruses and opportunistic infections, Chicago, IL., Feb. 1 - 5, 1998.14. Crumpacker CS, Sharma PL. Comparison of the loss of fitness for replication between two HIV RT variants, L74V and M184V. 2nd Interntional Workshop on HIV Drug Resistance & Treatment strategies, Lake Maggiore, Italy, June 24-27, 1998.15. Sharma PL, Crumpacker CS. Decreased processivity of HIV-1 reverse-transcriptase containing ddI-selected mutation Leu74Val. The 6th National Conference on Retroviruses and opportunistic infections, Chicago, IL., Jan. 31 to Feb. 4, 1999.16. Sharma PL, Amat C, Adams M, Mellors JW. and Schinazi RF. HIV-1 RT mutations K65R and L74V are incompatible in vitro. "HIV DART 2000" Frontiers in Drug Development for Antiretroviral Therapies, Isla Verde, Puerto Rico, Dec 17-21, 2000.17. Sharma PL, Amat C, Barnett T, Adams M, Crumpacker CS, and Schinazi RF. Double HIV mutants with L74V and M184V mutations retained their deleterious effect on viral replication. "HIV DART 2000" Frontiers in Drug Development for Antiretroviral Therapies, Isla Verde, Puerto Rico, Dec 17-21, 2000. 18. Sharma PL, Nurpeisov V, Skaggs S, and Schinazi RF. Optimal replication of double mutant K65R + L74V is required for the 65R K reversion. Oral presentation at The Ninth West Coast Retrovirus Meeting, Palm Springs, California, October 3-5, 2002.19. Nurpeisov V, Hurwitz S, Schinazi RF, Sharma PL. Development of fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of viruses containing mutations at HIV-1 reverse transcriptase codons 74 and 184. Third HIV DRP Symposium on Antiviral Drug Resistance Organized by HIV Drug Resistance Program, National Cancer Institute at Chantilly, Virginia, December 8-11, 2002. 20. Schinazi RF, Mellors J, Erickson-Vitanen S, Mathew J, Parikh U, Sharma P, Otto M, Yang Z, Chu CK, and Liotta DC. D-FDOC: a dioxolane pyrimidine nucleoside with activity against common nucleoside-resistant HIV-1. XI International HIV Drug Resistance Workshop, Seville, Spain, July 2-5, 2002. 21. Moser MJ, Sharma PL, Nurpeisov V, Schinazi RF, Prudent JR. Using GENE-CODE technology to detect early emerging populations of drug-resistant human immunodeficiency virus type 1. XII International HIV Drug Resistance Workshop, Los Cabos, Mexico, July 10-14, 2003. Ruckstuhl M, Moser MJ, Kozlowski M, Bassit L, Sharma PL, Prudent JR, and Schinazi RF. Quantifying mixed populations of drug resistant HIV-1 containing the M184V mutation. Bridging the Sciences HIV Vaccine Research and Drug Development May 19-20, 2005, Atlanta, Georgia. 22. Moser MJ, Sharma PL, Nurpeisov V, Schinazi RF, and Prudent JR. Detection of early emerging populations of drug- resistant human immunodeficiency virus type 1. 20th Annual Clinical Virology Symposium, April 25 - 28, 2004, Clearwater Beach, Florida. 23. Ruckstuhl M, Moser MJ, Kozlowski M, Bassit L, Sharma PL, Prudent JR, and Schinazi RF. Quantifying mixed populations of drug resistant HIV-1 containing the M184V 7mutation. Bridging the Sciences HIV Vaccine Research and Drug Development May 19-20, 2005, Atlanta, Georgia.24. Chunduri HB, Rimland D, Nurpeisov V, Crumpacker C, and Sharma PL. Differential reversion kinetics of HIV-1 reverse transcriptase key mutations: mechanism for the prevalance of nucleoside analog-selected mutations in patients.Meeting on Retroviruses at Cold Spring Harbor Laboratory, May 18-23, 2009, Cold Spring Harbor, New York. 25. Chunduri HB, Nurpeisov V, Crumpacker C, Rimland D, and Sharma PL. A leu Ile but not Leu Val change at HIV- 1 reverse transcriptase codon 74 leads to a replication competent virus in the background of K65R mutation. Meeting on Retroviruses at Cold Spring Harbor Laboratory, May 18-23, 2009, Cold Spring Harbor, New York. 26. Chunduri HB, Rimland D, Crumpacker C, and Sharma PL. Increased Processivity of HIV-1 Reverse Transcriptase Containing Leu74 Ile Change in the Background of Lys65Arg Leads to a Replication Competent virus. 10th Annual Symposium on Antiviral Drug Resistance, Nov. 15-18, 2009, Richmond, Virginia. 27. Chunduri H. B, Nurpeisov V, Crumpacker C, Rimland D., and Sharma PL. Reverse Transcriptase Mutation K65N Confers a Decreased Replication Capacity to HIV-1 in Comparison to K65R due to a Decreased RT Processivity.Retroviruses at Cold Spring Harbor, May 24-29, 2010. 28. Sharma PL, Chunduri HB, Wise J, Mindley R, and Rimland D. Up-Regulation of Anti-apoptosis and Down-Regulation of DNA Damage Response Markers in Human Peripheral Blood Mononuclear Cells by Viruses Containing K65R and MDR Mutations in Comparison to wild type Virus. Retroviruses at Cold Spring Harbor, May 24-29, 2010. SKILLS:1. Viral Cell Culture (Primary and Stable Cell Lines) 2. Molecular Biology (cloning, sequencing, expression of proteins, mutagenesis, sequence allignments, PCR, real time PCR, Used BioFire and Infinity machines for PCR).3. Diagnostic microbiology (Quality Control of Microbiology Lab., Reading and identification of pathogenic human pathogens).4. Biosafety audits of Laboratories (served as Biosafety Chair-person) 5. Computer skills: Word, Power point, Excel, using search engines for research. 6. Grant writing (Successful grant writing), Manuscript writing. 7. Supervisory experience as a Principle Investigator pf federally funded grants. 8. Harmonica player8References:David Rimland, M.D., Chief, Infectious Disease of VA ID Program and Professor of Medicine at Emory University School of Medicine and Veterans Affairs Medical Center, 1670 Clairmont Road, Decatur, GA 30033. Tel: PHONE NUMBER AVAILABLE ex. 6165; E- mail: EMAIL AVAILABLEJan Mead, Ph.D., Professor, Department of Pediatrics, Emory University School of Medicine and Atlanta VA Medical Center, 1670 Clairmont Road, Decatur, GA 30033. Tel: PHONE NUMBER AVAILABLE ex. 2545; E-mail: jmead@emory.edu Clyde S. Crumpacker, M.D., Professor of Medicine, Harvard School of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02115. Tel: PHONE NUMBER AVAILABLE; E-mail: EMAIL AVAILABLE Michael T. Fallon, DVM, PhD, DACLAM, CPIA, Chief Veterinary Medical Officer, Office of Research and Development, Veteran Health Administration, Department of Veterans Affairs, and Associate Professor, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Mailstop 508/151V; Room 4A106, Atlanta VA Medical Center, 1670 Clairmont Road, Decatur, GA 30033. Tel: PHONE NUMBER AVAILABLE; E-mail: EMAIL AVAILABLE Antonio Laracuente, MBA, Research Operation Director, Atlanta VA Medical Center. E-mail: EMAIL AVAILABLE; Tel: PHONE NUMBER AVAILABLE) |
